Plasma levels of immunosuppressive mediators during cardiopulmonary bypass

Mediators of Inflammation

Volumn 5, Issue 1, 1996, Pages 51-55

  Borrelli, E ^a   Giomarelli, P ^a   Naldini, A ^b   Luzzi, E ^b   Silvestri, S ^b   Bocci, V ^b   Gardinali, M ^c  

^a Institute of Thoracic and Cardiovascular Surgery

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiopulmonary bypass; Complement; Hypothermia; Normothermia; Transforming growth factor

Indexed keywords

COMPLEMENT COMPONENT C3A; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL;

EID: 0029988624     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935196000099     Document Type: Article

References (22)

1. Nilsson L, Brunnkvist S, Nilsson U, et al. Activation of inflammatory systems during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1988; 22: 51–57.
2. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845–857.
3. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304: 497–502.
4. Ide H, Kakiuchi T, Furuta N, et al The effect of cardiopulmonary bypass on T cells and their subpopulations. Ann Thorac Surg 1987; 44: 277–282.
5. Hisatomi K, Isomura T, Kawara T, et al. Changes in lymphocyte subsets, mitogen responsiveness, and interleukin-2 production after cardiac operations. J Thorac Cardiovasc Surg 1989; 98: 580–591.
6. Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363–372.
7. Naldini A, Borrelli E, Cesari S, Giomarelli P, Toscano M. In vitro cytokine production and T-cell proliferation in patients undergoing cardiopulmonary by-pass. Cytokine 1995; 7: 165–170.
8. Erdei A, Fust G, Gergely J. The role of C3 in the immune response. Immunol Today 1991; 12: 332–337.
9. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8: 1.
10. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988; 141: 690–698.
11. Lichtenstein SV, Ashe KA, El Dalati H, Cusimano RJ, Panos A, Slutsky AS. Warm heart surgery. J Thorac Cardiovasc Surg 1991; 101: 269–274.
12. Buckberg GD. Strategies and logic of cardioplegic delivery to prevent, avoid, and reverse ischemic and reperfusion damage. J Thorac Cardio-vasc Surg 1986; 93: 127–134.
13. Lichtenstein SV, Abel JG, Panos A, Slutsky AS, Salerno TA. Warm heart surgery: experience with long cross-clamp times. Ann Thorac Surg 1991; 52: 1009–1015.
14. Hugli TE, Chenoweth DE. Biological active peptides of complement techniques and significance of C3a and C5a measurements. In: Nakamura RM, Dito WR, Tucker III ES, eds. Clinical Laboratory Techniques for the 1980s. New York: Alan R. Liss, 1980; 443–460.
15. Lawrence DA, Pircher R, Krycève-Martinerie C, Jullien P. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984; 121: 184–188.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method 1983; 65: 55–63.
17. Brody JI, Pickering NJ, Fink GB, Behr ED. Altered lymphocyte subsets during cardiopulmonary bypass. Am J Clin Pathol 1987; 87: 626–628.
18. Hammerschmidt DE, Stroncek DF, Bowers TK. Complement activation and neutropenia during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 370–377.
19. Moore FD, Warner KG, Assousa S, Valeri CR, Khuri SF. The effects of complement activation during cardiopulmonary bypass. Ann Surg 1988; 208: 95–103.
20. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988; 140: 3026–3032.
21. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic cells. Cancer Immunol Immunother 1988; 26: 95–99.
22. Wahl SM. Transforming growth factor (3: the good, the bad, and the ugly. J Exp Med 1994; 180: 1587–1591.